← Back to Search

Unknown

GZR-18 for Type 2 Diabetes

Phase 1
Waitlist Available
Research Sponsored by Gan and Lee Pharmaceuticals, USA
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 720 hours
Awards & highlights

Study Summary

This trial is testing a new drug, GZR18, in healthy subjects. This is the first time the drug has been tested in humans.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 720 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 720 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Dose limiting toxicity
Secondary outcome measures
Glycosylated Hemoglobin
Maximum Plasma Concentration

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Drug:GZR-18 administered via subcutaneous injectionExperimental Treatment1 Intervention
For Assigned Interventions: GZR-18 administered once via subcutaneous injection at doses of 1.0 ug/kg, 5.0 ug/kg, 10.0 ug/kg, 20.0 ug/kg, 30.0 ug/kg, 40.0 ug/kg & 50.0 ug/kg
Group II: Placebo controlPlacebo Group1 Intervention
Commercially obtained sterile, normal saline for injection will be used as the matching placebo. Placebo will be dosed in an identical manner to active study drug. The volume of placebo will be calculated according to body weight using active drug dose for volume calculation in order to maintain the study blind.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
GZR-18
2022
Completed Phase 1
~30

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Gan and Lee Pharmaceuticals, USALead Sponsor
14 Previous Clinical Trials
2,427 Total Patients Enrolled
Jia Lu, MD/PhDStudy DirectorGan and Lee Pharmaceuticals, USA Corp
Kimberly Lazaroff, MSNStudy DirectorGan and Lee Pharmaceuticals, USA Corp
1 Previous Clinical Trials
19 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects
2022. "Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05328726.
~8 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top